Ergocalciferol and Hyperventilation - a phase IV clinical study of FDA data

Summary:

Hyperventilation is reported as a side effect among people who take Ergocalciferol (ergocalciferol), especially for people who are female, 30-39 old, also take Alvesco, and have Asthma.

The phase IV clinical study analyzes which people have Hyperventilation when taking Ergocalciferol. It is created by eHealthMe based on reports of 32,546 people who have side effects when taking Ergocalciferol from the FDA, and is updated regularly.

What is Ergocalciferol?

Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.

What is Hyperventilation?

Hyperventilation is found to be associated with 705 drugs and 1,444 conditions by eHealthMe. Check the latest studies of Hyperventilation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

32,546 people reported to have side effects when taking Ergocalciferol.
Among them, 30 people (0.09%) have Hyperventilation.

Could Ergocalciferol cause Hyperventilation?

Among these 30 people:

What is the gender of people who have Hyperventilation when taking Ergocalciferol? *

female: 96.55 %
male: 3.45 %

What is the age of people who have Hyperventilation when taking Ergocalciferol? *

What are other drugs people take besides Ergocalciferol? *

What are other side effects people have besides Hyperventilation? *

Nausea (feeling of having an urge to vomit): 28 people, 93.33%
Dizziness: 27 people, 90.00%
Cough: 26 people, 86.67%
Weakness: 26 people, 86.67%
Chest Pain: 26 people, 86.67%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 26 people, 86.67%
Wheezing (a high-pitched whistling sound made while you breath): 25 people, 83.33%
Asthma: 25 people, 83.33%
Dyspnea (difficult or laboured breathing): 25 people, 83.33%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 25 people, 83.33%

What are the existing conditions these people have? *

Asthma: 20 people, 66.67%
Urticaria (rash of round, red welts on the skin that itch intensely): 18 people, 60.00%
Pain: 5 people, 16.67%
Multiple Allergies (allergy to multiple agents): 3 people, 10.00%
Hypersensitivity: 3 people, 10.00%
Gait Disturbance: 2 people, 6.67%
Low Density Lipoprotein: 1 person, 3.33%
High Density Lipoprotein Abnormal: 1 person, 3.33%
Breast Cancer Female: 1 person, 3.33%
Breast Cancer: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ergocalciferol and have Hyperventilation?

- Check whether Hyperventilation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ergocalciferol:

Ergocalciferol (32,652 reports)

Browse all side effects of Ergocalciferol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperventilation:

Hyperventilation (705 drugs)

Browse all the conditions that are associated with Hyperventilation:

Hyperventilation (1,444 conditions)

Related publications that referenced our studies

Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on ergocalciferol (the active ingredients of Ergocalciferol) and Ergocalciferol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.